Forschungsschwerpunkte:

Tegenero has developed a unique approach to balance T cell activation and expansion by triggering co-stimulatory CD receptors with novel monoclonal antibodies that convert „co-stimulatory“ CD receptors. With its most advanced product candidate TGN 1412, a fully humanized CD28-SuperMABTM, Tegenero targets the most efficient Cd receptor that co-stimulates T cells in combination with the TCR. TGN1412 bypasses the requirement for TCR signalling and activates T cells regardless of their TCR specifity.